⌘K
Loading ticker…
As of 2026-08-24, Arbutus Biopharma Corporation Common Stock (ABUS) has a 3-month relative strength percentile of 80 within the TickerStance CS+ADRC universe (~5,000 tickers). Its Power rating (absolute 1–99) is 57. The current market Stance is 47.8 (Neutral). Sector: Healthcare, ranked 3 of 11. Average daily range 3.9%, relative volume 8.31×. TickerStance reports observed regime conditions across the full CS+ADRC universe; band assignment reflects current breadth, momentum, and macro inputs computed at the daily close. Percentile ranks run from 1 (weakest) to 99 (strongest) relative to all universe members on the same date.
Relative strength across horizons plus the leadership score.
Accumulation rating, relative volume, U/D ratio, breakout-day proof.
Diluted EPS, last 8 quarters. Positive EPS uses YoY change.
ABUS is held by 21 ETFs as of May 2026. Top owner: VTWO at 0.02% weight, $4M notional. Top 3 carry $9M.
Held by 43 ETFs · $88M across latest filings · largest weight 0.66% (BBC).
Top 10 by value, from SEC N-PORT-P filings dated May 2026.
| ETF | Weight | Value | Δ |
|---|---|---|---|
| VTWO | 0.02% | $4M | — |
| SCHASchwab U.S. Small-Cap ETF | 0.01% | $3M | — |
| VHTVanguard Health Care ETF | 0.01% | $2M | — |
| ESML | 0.05% | $1M | — |
| VTWG | 0.04% | $619K | — |
Strong relative strength with attention running hot versus its own recent norm. The trend is intact but well-noticed; elevated retail attention has historically been associated with softer forward returns. Context, not a call.
Measures how unusual this name’s public attention is against its own 90-day history — a surprise reading, not a ranking of how watched it is versus other stocks. Intel, not a signal.
Daily range, ATR, beta, and the math for a 1-ADR stop.
YoY sales growth, last 8 quarters. Sales must back the earnings story.
TTM operating margin. Expansion = real operating leverage.
YoY common shares outstanding. Down = buyback tailwind. Up > 2% = dilution flag.
Reported figures from SEC filings. No analyst estimates or forward guidance.
| 0.00% |
| $393K |
| — |
| VFMO | 0.02% | $300K | — |
| GSSC | 0.03% | $294K | — |
| QQQS | 0.40% | $75K | −0.10 pp |
| VTHRVanguard Russell 3000 ETF | 0.00% | $62K | — |
Showing 10 of 21 ETF owners.
As filed in N-PORT — quarterly holdings with up to ~60-day publication lag. Not live positioning.
Related searches
| Jan | Feb | Mar | Apr | May | Jun | Jul | Aug | Sep | Oct | Nov | Dec | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | ABUS Jan avg: 2.92% median: -1.68% win: 50% σ: 18.69% n: 4 2022-04-12 → 2026-07-31 | ABUS Feb avg: 6.73% median: 8.22% win: 75% σ: 11.31% n: 4 2022-04-12 → 2026-07-31 | ABUS Mar avg: -0.29% median: -1.14% win: 50% σ: 7.20% n: 4 2022-04-12 → 2026-07-31 | ABUS Apr avg: -6.44% median: -6.67% win: 40% σ: 10.26% n: 5 2022-04-12 → 2026-07-31 | ABUS May avg: 5.96% median: 4.29% win: 60% σ: 10.91% n: 5 2022-04-12 → 2026-07-31 | ABUS Jun avg: -1.38% median: -7.63% win: 40% σ: 9.20% n: 5 2022-04-12 → 2026-07-31 | ABUS Jul avg: -0.37% median: -5.65% win: 40% σ: 14.69% n: 5 2022-04-12 → 2026-07-31 | ABUS Aug avg: 1.35% median: -0.62% win: 50% σ: 8.72% n: 4 2022-04-12 → 2026-07-31 (current) | ABUS Sep avg: 1.97% median: -0.26% win: 25% σ: 15.06% n: 4 2022-04-12 → 2026-07-31 | ABUS Oct avg: 4.18% median: 2.03% win: 50% σ: 13.56% n: 4 2022-04-12 → 2026-07-31 | ABUS Nov avg: -1.08% median: -3.17% win: 50% σ: 9.77% n: 4 2022-04-12 → 2026-07-31 | ABUS Dec avg: 6.17% median: 4.11% win: 50% σ: 12.15% n: 4 2022-04-12 → 2026-07-31 |